Skip to main content

Market Overview

UPDATE: Benchmark Upgrades RTI Biologics from Hold to BUY

Share:

Benchmark has published a report on RTI Biologics (NASDAQ: RTIX) upgrading the company from Hold to Buy.

In the report, Benchmark wrote, "We are upgrading RTIX shares to Buy from Hold based on stronger then anticipated earnings and our view that Spine risks are abating. RTI's performance is remarkable in contrast with continued difficult Spine and Dental market trends. RTI reported Q2 EPS of $0.04, which exceeded our consensus-matching $0.03 forecast. Revenue of $43.5 million exceeded the $40.5 million consensus and our $40.9 million forecast. We increased our 2012 EPS forecast to $0.18, from $0.15, but our $0.12 current-year forecast is unchanged. We increased our price target to $4.00, from $3.00, based on shifting our valuation basis to 2012. We continue to employ a 20x EPS multiple and add net cash, which has increased to $0.64 per share."

Benchmark raises the rating for RTI Biologics from Hold to BUY with a price target of $4.00. RTI Biologics closed Thursday at $2.98.

 

Related Articles (RTIX)

View Comments and Join the Discussion!

Posted-In: Benchmark RTI BiologicsAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com